Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729101 | 0.79 | TAAR1 (0.43) | TAAR1CYP2D6TSHRTBXAS1CXCR4 | |
| SCHEMBL4777900 | 0.78 | CXCR4 (0.45) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| SCHEMBL24549760 | 0.75 | TBXAS1 (0.50) | TAAR1LMNASMN1; SMN2TBXAS1HTR1A | |
| SCHEMBL12853915 | 0.75 | TAAR1 (0.54) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| SCHEMBL11936762 | 0.74 | TAAR1 (0.57) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| SCHEMBL27938415 | 0.74 | TAAR1 (0.57) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| SCHEMBL14856665 | 0.74 | TAAR1 (0.53) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| SCHEMBL12193521 | 0.73 | TAAR1 (0.56) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 | |
| Acetic Acid SCHEMBL27984534 | 0.73 | TAAR1 (0.50) | TAAR1SMN1; SMN2TBXAS1HTR1AFDPS | |
| SCHEMBL1331599 | 0.72 | TAAR1 (0.54) | TAAR1CYP2D6TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885CYP2D6 2020/4885TSHR 4700/4885 |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885CYP2D6 2020/4885TSHR 4700/4885 |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885CYP2D6 2020/4885TSHR 4700/4885 |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885CYP2D6 2020/4885TSHR 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.